Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented
bone loss after weight loss obtained through a low calorie-diet, supporting its role as a safe
weight-lowering agent (JCEM)
Diabetes News
Tag: GLP1
Expedited Biliopancreatic Juice Flow to the Distal Gut Benefits the Diabetes Control After Duodenal-Jejunal Bypass
Expedited biliopancreatic juice flow to the distal gut was associated with augmented GLP-1 secretion and increased fasting serum TBA concentration, which may partly explain the metabolic benefits of DJB (Obesity Surgery)
Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes
Novo Nordisk today announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks
Cord Serum Dipeptidyl-Peptidase 4 Activity in Gestational Diabetes
Decreased cord serum DPP4 activity in gestational diabetes mellitus might be the result of an adaptive fetal response or an early dysregulation in the entero-insular axis with consequences beyond the incretin system. Cord plasma GLP-1 levels may reflect the missing oral intake with a limited glucose sensing of L-Cells via the circulation in fetal life (European Journal of Clinical Investigation)
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Our results suggest GLP-1 RAs are promising candidates for weight control in comparison with traditional hypoglycemic drugs (Journal of Diabetes Research)
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss (Diabetes)
Oramed Granted Patent in Israel for Oral Administration of GLP-1
The Israel Patent Office has granted the Company’s patent for its invention, titled “ Methods and Compositions for Oral Administrations of Exenatide.” (Oramed)
Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study
A short course of treatment with GLP-1 RA, besides weight loss, induces a redistribution of adipose tissue deposits, possibly contributing to a better cardiovascular risk profile in patients with type 2 diabetes mellitus (Acta Diabetologica)
Glycosmedia is also available as an App: